- Home
- OPRX vs APLT Comparison
OPRX vs APLT Comparison
Compare OPRX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRX
- APLT
- Stock Information
- Founded
- OPRX 2006
- APLT 2016
- Country
- OPRX United States
- APLT United States
- Employees
- OPRX N/A
- APLT N/A
- Industry
- OPRX Business Services
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- OPRX Consumer Discretionary
- APLT Health Care
- Exchange
- OPRX Nasdaq
- APLT Nasdaq
- Market Cap
- OPRX 154.0M
- APLT 37.5M
- IPO Year
- OPRX N/A
- APLT 2019
- Fundamental
- Price
- OPRX $8.72
- APLT $0.40
- Analyst Decision
- OPRX Buy
- APLT Buy
- Analyst Count
- OPRX 8
- APLT 7
- Target Price
- OPRX $9.06
- APLT $6.10
- AVG Volume (30 Days)
- OPRX 231.5K
- APLT 2.5M
- Earning Date
- OPRX 05-12-2025
- APLT 04-14-2025
- Dividend Yield
- OPRX N/A
- APLT N/A
- EPS Growth
- OPRX N/A
- APLT N/A
- EPS
- OPRX N/A
- APLT N/A
- Revenue
- OPRX $92,127,000.00
- APLT $455,000.00
- Revenue This Year
- OPRX $12.12
- APLT $1,768.13
- Revenue Next Year
- OPRX $10.87
- APLT $361.28
- P/E Ratio
- OPRX N/A
- APLT N/A
- Revenue Growth
- OPRX 28.81
- APLT N/A
- 52 Week Low
- OPRX $3.78
- APLT $0.30
- 52 Week High
- OPRX $14.13
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- OPRX 54.56
- APLT 47.17
- Support Level
- OPRX $8.09
- APLT $0.31
- Resistance Level
- OPRX $8.92
- APLT $0.43
- Average True Range (ATR)
- OPRX 0.64
- APLT 0.05
- MACD
- OPRX -0.07
- APLT 0.01
- Stochastic Oscillator
- OPRX 69.34
- APLT 77.39
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.